Onderzoek naar het voorspellen van het effect van biologicals op de ziekteactiviteit van een individuele patiënt met reumatoïde artritis (RA)
Completed
- Conditions
- Rheumatoid arthritis. Biologics. Prediction. Ex-vivo cytokine profiling.
- Registration Number
- NL-OMON26414
- Lead Sponsor
- Sint Maartenskliniek Nijmegen
- Brief Summary
https://pubmed.ncbi.nlm.nih.gov/30767874/
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 400
Inclusion Criteria
1. Rheumatoid arthritis (either 2010 ACR RA and/or 1987 RA criteria and/or clinical diagnosis of the treating rheumatologist, fulfilled at any time point between start of the disease and inclusion)
2. Patients with RA who start with (or switch to) biological therapy (including abatacept, adalimumab, etanercept, rituximab and tocilizumab)
Exclusion Criteria
None
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Individual treatment response prediction based on the European League against Rheumatism (EULAR) good response criteria after 3 months of treatment with the biologic.
- Secondary Outcome Measures
Name Time Method 1. Response prediction based on the European League against Rheumatism (EULAR) response criteria after 6 months of treatment with the biologic.<br /><br>2. Response prediction based on ∆DAS28CRP response criteria, after 3 and 6 months of treatment with the biologic.<br /><br>3. Response prediction based on ACR/EULAR remission criteria, after 3 and 6 months of treatment with the biologic.